Daptomycin and linezolid may have more favorable safety and efficacy profiles compared to vancomycin and require less therapeutic monitoring. To capitalize on these advantages, the University of Colorado Hospital relaxed prescribing restrictions and updated local guidance for the treatment of Gram-positive infections, resulting in increased daptomycin and linezolid utilization. The objective of this study was to assess the impact of liberalized daptomycin and linezolid use on minimum inhibitory concentrations (MICs) in Gram-positive organisms.MethodsThis retrospective, single-center study included all Staphylococcus and Enterococcus isolates across an 8-year period, including a 3-year follow-up period after implementing practice changes. Organisms were categorized as hospital-acquired (HA) if the culture was collected 48 hours after admission. Interrupted time series analyses were performed to measure changes in geometric mean (GM) of MICs before and after implementation.ResultsMinimum inhibitory concentrations from 19 160 isolates were evaluated, of which 7224 were HA. Linezolid use increased to 43.7 days of therapy per 1000 patient days (DOT/1000PD), and daptomycin use increased to 15.7 DOT/1000PD post-implementation. Linezolid GM MICs trended downward pre-implementation, and the trajectory was unaffected by implementation except in coagulase-negative Staphylococcus (CoNS). Daptomycin GM MICs declined pre-implementation among Enterococcus, but not Staphylococcus. Implementation was associated with a significant slope change in vancomycin-resistant Enterococcus (VRE) and HA CoNS. Resistance rates and MIC distributions were not impacted by implementation.ConclusionsThe liberalization of daptomycin and linezolid did not result in clinically relevant increases in resistance. Further studies are needed to confirm the durability of these results, specifically among CoNS and VRE.

Researchers have developed a wearable microneedle patch that monitors drug levels. In preclinical studies, the device tracked vancomycin levels, supporting continued development for personalized drug...

AbstractBackground. Vancomycin taper followed by pulse and fidaxomicin are two common treatments for recurrent C. difficile infection (rCDI) but they have

AUC₂₄-based MIPD for vancomycin improved therapeutic target attainment and was associated with a lower observed incidence of AKI. These findings support further evaluation of AUC-guided dosing...

Fam K. et al. identified peptidoglycan hydrolase SagA that modulates antibiotic susceptibility of vancomycin-resistant Enterococcus faecium. Pharmacological inhibition of SagA restored vancomycin efficacy across multidrug-resistant clinical strains.

Fam K. et al. identified peptidoglycan hydrolase SagA that modulates antibiotic susceptibility of vancomycin-resistant Enterococcus faecium. Pharmacological inhibition of SagA restored vancomycin effi...

Ein kleines Molekül macht das besiegte Antibiotikum Vancomycin wieder wirksam gegen gefürchtete resistente Superkeime aus Kliniken.

Mesh-associated infection after EMR is devastating and difficult to treat. These preclinical findings suggest that local vancomycin delivery may serve as an adjunct to systemic prophylaxis, warranting...

In this single-center Aseer surveillance, MRSA became the majority of S. aureus during 2013-2024 and showed broad multidrug non-susceptibility, while vancomycin and daptomycin retained full in vitro activity....

Abstract. Small RNAs (sRNAs) play a crucial role in modulating target gene expression through short base-pairing interactions and serve as integral compone

Nutromics has been granted FDA Breakthrough Device Designation for our first product in development: a wearable patch for vancomycin therapeutic drug monitoring.   The FDA's Breakthrough Device Progra...

Dosing critical antibiotics is currently a dangerous guessing game played with delayed blood tests.

Clostridioides difficile infection is a common cause of clinically significant diarrhea, often becomes recurrent, and can be fatal when severe or fulminant. The purpose of this America Gastroenterological Association (AGA) Clinical Practice Update Expert Review is to provide best practice advice for C difficile infection management.

Current Infectious Diseases Society of America guidelines recommend the use of vancomycin (VAN) or daptomycin (DAP) monotherapy for the management of methicillin-resistant Staphylococcus aureus bloods...